Donor specific antibody (DSA) detection techniques include various tests, which identify anti-HLA antibodies of the immunoglobulin (IG) isotypes by flow cytometry or by beads coated with single HLA antigen bead (SAB) assays using Luminex platform. Patients, considered non-sensitized by complement dependent cytotoxicity (CDC) assay, can have HLA antibody detectable by flow or SAB assays, and these antibodies may be associated with a higher risk of rejection and graft loss. De-novo DSA has been considered as a biomarker of rejection. Despite the high sensitivity and specificity, SAB assays are overtly sensitive. They can detect low level DSA and antibodies that can bind but not fix complement, and thus not initiate the complement cascade. These antibodies may not cause graft injury. CDC-positive antibodies are capable of activating the complement cascade through the classical pathway and are known to be clinically relevant. CDC test has low sensitivity and specificity. Accurate definition of exact HLA antibody specificities by CDC is limited in patients with high panel reactive antibody (PRA).
Virtual cross match (VXM): Patients can undergo successful kidney transplant with ''incompatible'' donors in the presence of DSA detected by the Luminex-SAB assays. In USA, HLA antigens can be entered into UNet, a secured Internet-based transplant information database created by United Network for Organ Sharing (UNOS) as ''avoids,'' based on SAB assay of patients waiting for transplant and a VXM can be done once the complete molecular HLA typing of donor is available. This helps to reduce the risk for antibody-mediated graft loss. Presence of DSA detected by SAB assays prolongs the waiting period significantly, especially among very highly sensitized patients and has disproportionately affected waiting period of pediatric patients. That is why, these two groups are given priority points in the new UNOS allocation system. Desensitization strategies with potent immunosuppressive regimens can also be used, but it puts patients at risk for drug-related morbidity and mortality. Because not all patients can be desensitized and wait-list mortality can be a problem, highrisk transplants across positive cross-matches or positive DSAs have been performed. Determining which antibodies are clinically relevant and should be considered as ''avoids'' is of paramount importance for the potential recipient and for organ allocation.
Using the best attributes of sensitivity, specificity, and risk of graft rejection of both the CDC and the IgG SAB assays, a novel C1q-binding assay has been developed to define a sub-set of antibodies that are likely to be clinically significant and having the specificity and sensitivity of the SAB assay. 1, 2 Binding of the first component of complement (C1q) is a required step for activation of the complement cascade through the classic pathway leading to cell injury. The C1q binding SAB assay detects only that sub-set of HLA antibodies capable of binding human C1q resulting in complement activation.
The hypothesis and interpretation of C1q binding SAB assay are: 3 1. If C1q binding DSA is present before transplant and persists after transplant, or if DSA gets converted from IgG positive/ C1q negative to IgG positive/C1q positive within the week after transplant, the recipient would have antibody-mediated rejection (AMR). 2. Patients, who are solely IgG VXM positive but C1q negative, are not at risk for early AMR. Thus C1q binding SAB assay can much better characterize DSA and VXM.
Assessment of HLA antibodies using the IgG SAB assay:
Patient sera are analyzed using a Luminex platform and various commercially available SAB kits (LABScreen One Lambda Inc., LIFECODES Immucor Transplant Diagnostics Inc.). This assay uses a pool of differentially fluoresceinated beads, each coated with a single different purified, singlecloned HLA class I or class II antigen. Collectively, there are beads representing 96 class I (A, B, C) and 56 class II (DR, DQ, DP) antigens/alleles. Cut-offs for positive reactions (''true'' antibodies) as well as ''possible'' antibodies have been determined to be greater than 1000 MFI and 500-999 MFI, respectively. This assay detects all IgG antibodies irrespective of their complement-fixing ability. Cutoffs MFI of more than 1500 for pre-transplant DSA and more than 1000 MFI for post-transplant de-novo DSA are considered significant. Each lab needs to have its own cutoff values for defining significant positive DSA. Some labs i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 2 7 -1 2 9
Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/ijt consider even more than 500 MFI significant for posttransplant de novo DSA.
IgG subclass assay and definition of IgG subclass pattern:
The IgG subclass assay is performed as the standard SAB assay which is modified by replacing the generic reporter antibody IgG-pan (OneLambda) by monoclonal reporter antibodies specific for IgG1-4 subclasses (IgG1 clone HP6001, IgG2 clone 31-7-4, IgG3 clone HP6050, IgG4 clone HP6025; Southern Biotech, www.southernbiotech.com). A positive result was defined by a MFI value greater than a cutoff that was generated for each IgG subclass and for every individual bead by using four negative control sera (NC1-4) from healthy, non-sensitized, and HLA antibody-negative patients mean:
To estimate the amount of IgG subclasses, the ratio greater than the corresponding cutoff (i.e., ratio = MFI IgG subclass divided by MFI cutoff). Based on these results, the definition of the IgG subclass pattern and the percentage of strong C-binding subclasses among the total IgG are as follows:
1. Isolated strong C-binding (IgG1 and IgG3). 2. Isolated weak or no C-binding group (IgG2 and IgG4). 3. Mixture of strong and weak or no C-binding. % strong C binding subclasses
Assessment of HLA antibodies using the C1q SAB assay:
Complement (C) activation is an important effector mechanism after binding of donor-specific human leukocyte antigen (HLA) antibodies (DSAs) to target HLA molecules. Complement-induced damage can be mediated by the membrane attack complex, leading to cell lysis or by earlier C components creating an inflammatory environment. The C cascade is initiated by the binding of C1q, which requires binding sites on at least two antibodies in close steric proximity. In the context of IgG DSA, C1q binding thus depends on the density of HLA molecules on target cells, the density of bound DSA, and their IgG subclass. The single HLA bead (SAB) assay has revolutionized detection and specification of HLA antibodies. Because the HLA molecule density on SAB is very high, C1q binding to IgG HLA antibodies on SAB mainly depends on the density of bound HLA antibodies and their IgG subclass. The density of bound HLA antibodies itself is related to their amount, avidity, and specificity. In the standard SAB assay, IgG HLA antibody binding is measured by an anti-human IgG antibody detecting all IgG subclasses and is reported as mean fluorescence intensity (MFI). Recently, a modified SAB test measuring C1q binding to HLA antibodies has been introduced. Although some studies reported a strong association of the MFI in the standard SAB assay with C1q binding, others found that MFI values are not a suitable surrogate for C1q binding. Sera are tested in parallel with substitution of a purified anti-human C1q (hC1q) second step. Sera are first decomplemented (56 8C for 30 min) and then spiked with 150 g/ml purified hC1q (Sigma, St Louis) to introduce uniformity and adequate C1q concentrations into all specimens. Serum (5 ml) was incubated with LABScreen class I and class II SAB (2.5 ml) for 20 min at room temperature and then custom-labeled with phycoerythrin-conjugated anti-hC1q (10 ml, phycoerythrin-anti-hC1q, Biodesign, Intl, Saco, ME). After an additional 20 min of incubation at room temperature, the beads are washed twice and acquired on a Luminex machine. Data are analyzed as for the IgG SAB assay, with the exception that no standard cutoff values are used, but rather, comparisons are made to the background MFI, and any increases exceeding 50% over background are considered positive. This technique detects only that sub-set of IgG antibodies that can bind hC1q.
C4d SAB studies by Smith It is a standardized assay in which a constant and physiologic amount of hC1q is used. It does not depend on screening ''normal'' individuals for the best, but limited, source of whole human complement. It is also not complicated by the fact that some human sera have inhibitory factors that actually reduce binding of complement (e.g., use of intravenous IgG). The IgG subclass composition of HLA antibodies as an important determinant for C1q binding. Thus, factors that critically influence C1q binding to HLA antibodies on SAB are currently not well defined. In addition, the impact of an antihuman globulin (AHG) enhancement on the ability to detect C1q binding HLA antibodies is not defined. The C1q binding is strongly related to the density of HLA antibody on SAB reflected by IgG MFI. The subclass composition had a minor effect on C1q binding mainly because strong C-binding IgG subclasses dominate regarding their frequency and relative amounts. This has important implications, because a negative standard C1q result does not mean that the investigated HLA antibodies do not have the biologic capability to activate the C-system. Indeed, 93% of HLA antibodies, which do not induce standard C1q positivity defined by a cutoff value of MFI of more than 500, contain C1q-binding IgG subclasses of the IgG1 and IgG3 types. If present in higher quantities, these HLA antibodies will lead to C1q binding in most cases. Therefore, considering pre-transplantation standard C1qnegative DSA as clinically not relevant can be misleading, because a strong and durable post-transplantation memory response could significantly increase the amount of DSA reaching the threshold density on target cells to initiate the C-cascade.
Studies suggest that C1q binding of pre-transplantation DSA did not increase prediction of AMR and allograft loss beyond IgG defined DSA. By contrast, post-transplantation C1q binding DSA indicating a strong and durable immune response with high-i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 2 7 -1 2 9
level DSA containing C-binding IgG subclasses were associated with an increased risk for allograft loss. Nevertheless, there remain C1q results, which are not well reflected by the IgG MFI. Notably, the IgG MFI indicates binding of HLA antibodies to SAB, which is related to the amount and avidity of the HLA antibody. However, measuring ''just binding'' cannot assess the HLA antibody density on individual HLA molecules. Indeed, it has been elegantly shown that two HLA antibodies directed against different epitopes on the same HLA molecule can very efficiently and activate the C-system, although this is not the case if only a mono-specific HLA antibody is used at similar concentration. In addition, it has been recently suggested that the ability of an antibody to bind C1q and to subsequently initiate the complement cascade depends on conformational changes that only some HLA epitopes can induce. Thus, some of the missing correlation between IgG MFI and C1q positivity might be related to the specificities of the HLA antibodies.
IgG1 and IgG3 subclasses account for the quantitative majority of HLA antibodies. This predominance of IgG1 and IgG3 is the reason why adding the IgG subclass information can only marginally improve the ability to predict C1q binding based on IgG MFI. Lowe et al. investigating 138 HLA specificities from 51 sensitized patients found very similar IgG subclass pattern, and IgG1 and IgG3 accounted for 91% of the total IgG. 4 Attempt to increase detection of low level C-binding HLA antibodies by the addition and use of AHG to the standard C1q assay significantly increased the signal across all IgG subclass compositions but mainly in the IgG range of 5000-20,000 MFI. This is consistent with the concept that AHG can enhance C1q binding for IgG1, IgG2, and IgG3 subclasses by providing additional C-binding receptors. So far, the AHG C1q assay has not been evaluated for its clinical utility.
C1q binding is strongly related to the density of HLA antibody on SAB reflected by IgG MFI. The IgG subclass composition has a minor effect on C1q binding mainly because C-binding IgG subclasses dominate regarding frequency and relative amounts. A negative C1q assay result also does not indicate the absence of strong C-binding IgG subclasses.
Loupy et al. have demonstrated that the occurrence after transplantation of higher graft loss rate in patients with complement-binding DSA was attributable to a higher rate of AMR, especially in the patients who developed complementbinding DSA de novo after kidney transplantation. 2 Interestingly, pre-transplant complement-binding DSA did not have the same predictive values, since about half of the patients lost these antibodies after transplantation.
